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The immune responses of mice to pneumococcal polysaccharide antigens are remarkably similar to those of humans
in that both neonates and aged individuals are hyporesponsive to these antigens (9, 18, 22, 30, 31). Not surprisingly,
there is an increased susceptibility of infants and aged
humans to pneumococcal infections (18, 28, 36). A 23-valent
pneumococcal polysaccharide vaccine was developed in
1983 to improve antibody responses in humans to encapsulated bacteria and was found to be protective in young adults
but not in infants (8, 20). The efficacy of this vaccine in the
elderly has been extremely controversial (29). Despite large
immunization programs, bacterial pneumonia remains a serious cause of morbidity and mortality throughout the world
and a significant cause of illness and death among the
elderly. The mechanistic basis of this age-associated variation in immunity to polysaccharide antigens is not known.
Further, the mucosal lymphoid apparatus, encompassing
over a third of the body's lymphoid tissue and forming the
first line of defense in infections, has recently been shown to
retain immunocompetence in aged mice (33). This is interesting in the context of our recent findings which showed
that a variety of type 2 thymus-independent antigens (TI-2)
elicited excellent antibody responses from the spleen and
mesenteric lymph nodes (MLN) but not from peripheral
lymph nodes or lungs (15-17) and because pneumococcal
polysaccharides have been considered TI-2 antigens (21).
To gain further insight into the effects of aging on the
immune responses to pneumococcal polysaccharide antigens, we established a murine model system using the
Pnu-Imune vaccine as the antigen. The polyvalent pneumococcal vaccine is a mixture of 23 capsular polysaccharides

*

derived from the most commonly occurring serotypes of
pneumococcal bacteria (12). In spite of extensive work with
individual polysaccharides in the animal models, very little
information is available about the characteristics of the
immune responses of mice to this vaccine formulation. Such
studies will be extremely important in improving the efficacy
of this vaccine in children and the elderly. This work has
focused on characterizing murine immune responses to the
vaccine and analyzing the age-associated changes in such
immune responses in systemic (spleen and peripheral lymph
nodes) and mucosa-associated lymphoid organs (MLN).
Procedures were developed to measure specific antibody
response to the whole Pnu-Imune vaccine. The plaqueforming cell (PFC) response of spleen cells to pneumococal
polysaccharides declined with age, whereas responses of the
MLN increased or remained unchanged over a comparable
age span. The data supports the hypothesis that B-cell
responses of mucosal and systemic lymphoid organs diverge
with age. Moreover, monophosphoryl lipid A [MPL(A)], a
nontoxic adjuvant (26, 27), when given along with the
Pnu-Imune vaccine, enhanced the immune responses to the
vaccine in the spleens of aged mice and induced an immunoglobulin G (IgG) response to the vaccine.
MATERIALS AND METHODS
Mice. Female BALB/c-CRL mice of various ages, ranging
from 4 to 28 months, were obtained from the National
Institute of Aging (Bethesda, Md.) and the National Cancer
Institute through Charles River Laboratories (Kingston,
N.Y.). CB17 mice of age 5 to 16 months were bred in our
animal colony.
Reagents. A 23-valent pneumococcal vaccine (i.e., PnuImune 23) was obtained from Lederle Laboratories (Pearl
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A murine model system was established to study immune responses to the Pnu-Imune vaccine, which is made
different pneumococcal capsular polysaccharides. In this animal model, antibody-forming cell
to 21 of 23 individual polysaccharides in the vaccine were detected. The Pnu-Imune vaccine elicited
good antibody responses from the spleens and mesenteric lymph nodes (MLN) of young mice, whereas a variety
of other peripheral lymph nodes were unresponsive. The immunoglobulin M plaque-forming cell (PFC)
response in the spleen to the Pnu-Imune vaccine (given intraperitoneally or subcutaneously) decreased
dramatically with increasing age. However, the spleen and MLN differed in their susceptibility to an
age-associated decline in immune function. While the PFC responses in the spleen declined with age, the PFC
response in the mucosa-associated MLN did not decline with age but instead remained constant over the entire
age span of 4 to 28 months studied. These studies showed that the spleen, peripheral lymph nodes, and MLN
did not demonstrate parallel age-associated defects in antibody responses to pneumococcal polysaccharides
when the antigen was administered systemically. Also, the deficient splenic antibody response to Pnu-Imune
vaccine in aged mice could be enhanced by injecting a combination of Pnu-Imune vaccine and the nontoxic
adjuvant monophosphoryl lipid A. Moreover, an immunoglobulin G response was induced when the
immunogen was a mixture of vaccine and adjuvant.
up of 23
responses
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River, N.Y.). MPL(A) (i.e., monophosphoryl lipid [MPL]
plus trehalose dimycolate mixture emulsion) was purchased
from RIBI Immunochemical Research Inc. (Hamilton, Mont.).
Trinitrophenylated Brucella abortus (TNP-BA) was prepared as described before (17).
Immunization procedure. Mice were given a single intraperitoneal (i.p.) or subcutaneous injection of the optimal
dose of Pnu-Imune vaccine (11.5 ,ug per mouse) or individual
polysaccharide (0.5 ,ug per mouse) in saline alone or along
with 25 ,ug of MPL(A) adjuvant. In these studies, the optimal
dose of the vaccine was found to be the same for all the age
groups of BALB/c mice examined. MPL(A) was reconstituted to 0.5 mg/ml in saline and mixed thoroughly to obtain
an opalescent stock solution, which was stored at 4°C until
Cell preparation. Lymphoid cells to be assayed were
obtained from the spleens, MLN, and peripheral lymph
nodes, which included brachial, axillary, inguinal, cervical,
popliteal, and periaortic lymph nodes. Adhering fat and
connective tissues were removed from the lymphoid tissues.
Lymphocytes were dispersed by pressing the spleens or
lymph nodes against the bottom of a petri dish containing
Hanks balanced salt solution using the flat surface of a sterile
disposable syringe plunger. A mixture of serum-free Iscove's solution and Ham's F12 solution was supplemented
with 10% fetal calf serum and was employed for all studies
with lymph node cells (32). The spleens and lymph node cells
were washed with Hanks balanced salt solution and were
resuspended in the mixture of Iscove's and Ham's F12
solutions plus 10% fetal calf serum for assay.
Hemolytic PFC assay. The numbers of antibody-producing
PFCs specific for pneumococcal polysaccharides were detected in individual mice. PFCs that made IgM antibodies
were detected by a slide version of the technique of localized
hemolysis in gel (19) by using indicator sheep erythrocytes
(SRBC) coated with Pnu-Imune vaccine or individual
polysaccharides or trinitrophenyl groups. The procedure
described by Baker et al. (5) was employed to couple
polysaccharides to SRBC. Briefly, this procedure consisted
of washing the SRBC, coating with Pnu-Imune vaccine
(1,000 ,ug/0.5 ml of packed SRBC) or individual polysaccharide (350 ,ug/0.5 ml of packed SRBC), and coupling with 1.0
ml of 0.1% freshly made chromium chloride solution. The
suspension was rocked for 10 min at room temperature. The
erythrocytes were then washed four times by centrifugation
with 20 volumes of saline and adjusted to a final concentration of 10% (vol/vol) for use in the PFC assays. TNP-SRBC
were prepared as described before (17).
Polyethylene glycol (average molecular weight, 7,500 to
8,000) (J. T. Baker Chemical Co., Phillipsburg, N.J.) was
added to the reaction mixture containing 0.5% melted SeaPlaque agarose (FMC Bioproducts, Rockland, Maine), lymphocytes, and antigen-coupled SRBC at a final concentration
of 0.25% (wt/vol) to improve the clarity of the plaques. The
number of PFCs on uncoupled SRBC was evaluated routinely and was found to be small (10 to 20 PFC/106 cells) and
was subtracted from all experimental values of Pnu-Imune
PFC reported here. PFC responses are expressed as the
mean numbers (arithmetic means + standard errors) of PFCs
per lymphoid tissue for groups of three to six mice.
PFCs of the IgG isotype were detected by inhibiting the
IgM plaques with a 1:100 dilution of goat anti-mouse IgM
serum (Sigma Chemical Company, St. Louis, Mo.) which
was added to the plaquing mixture and by facilitating the
development of IgGl, IgG2, and IgG3 plaques, with the
addition of predetermined optimal concentrations (1:80 dilu-

tion) of rabbit anti-mouse IgGl, IgG2, and IgG3 antisera,
respectively (Nordic Immunological Laboratories, Tilburg,
The Netherlands) to the plaquing mixture. This is known as
indirect-plaque assay, a well-established procedure that detects all IgG isotypes irrespective of their ability to fix
complement (16, 24).
Statistical analysis. The Student t test was used to assess
the significance of the observed differences between groups.
The differences were considered to be significant when the
probability (P) value was <0.05.
RESULTS
Characterization of immune responses of mice to PnuImune vaccine. A systematic analysis of doses, time periods,
and various routes of immunization was performed to establish conditions for obtaining maximum response to the
Pnu-Imune vaccine. Figure 1A summarizes the Pnu-Imunespecific response in the spleens and the MLN of BALB/c
mice immunized i.p. with various doses of the vaccine. For
both lymphoid organs, 11.5 p,g of the vaccine was found to
be the optimal dose that elicited the highest response. The
PFC response peaked 5 days after i.p. immunization, and the
peak responses in the spleen and MLN were obtained on the
same day (Fig. 1B). The splenic response to i.p. challenge
(636 + 96 PFCs/106 cells) was always higher than obtained
upon subcutaneous immunization (341 + 46 PFCs/106 cells)
or intravenous immunization (140 ± 8 PFCs/106 cells). The
MLN response was obtained only by i.p. immunization and
was always less than the splenic response, possibly because
i.p. immunization may not be the optimal route to elicit
immune responses from this tissue.
The PFCs detected with the vaccine-coated SRBC were
specific to Pnu-Imune vaccine, because the soluble vaccine
inhibited the response completely, whereas only 10 to 20%
of the response was inhibitable by cell wall polysaccharides
or type 3 pneumococcal polysaccharide. The immunization
procedure appeared to sensitize mice to almost all the
polysaccharides, as determined by using SRBC coated with
individual polysaccharides (21 of 23 were tested).
A sample of data (covering the whole spectrum of responses) with several polysaccharides is shown in Table 1.
The response measured on vaccine-coated SRBC was 1,034
± 141 PFCs/106 spleen cells, whereas the sum of responses
measured using individual-polysaccharide-coated SRBC was
2,950 ± 130 PFCs/106 cells, suggesting that the former is on
the average 33% as efficient in detecting the response to any
individual component.
Differences in splenic and lymph node responses to PnuImune. Previously we reported that TI-2 antigens like TNPFicoll elicited PFC responses from spleen and MLN B cells
but not from draining lymph node B cells in the periphery
(15, 17). To determine whether Pnu-Imune vaccine behaved
like the other TI-2 antigens and whether MLN response can
be obtained by another route of immunization, the vaccine
was administered subcutaneously and the PFC response was
measured in the peripheral lymph nodes (brachial, axillary,
cervical, popliteal, inguinal, and periaortic) and MLN as
well as in the spleen. Pnu-Imune vaccine did not elicit any
PFC response in the peripheral lymph nodes and MLN but
was effective in inducing a good splenic response (Fig. 2A).
Although the experiment was performed with the optimal
dose of the antigen (11.5 ,ug), other doses (higher and lower)
of the vaccine were also ineffective in eliciting a PFC
response from the peripheral lymph nodes. In the same
experiment, TNP-BA, a TI-1 antigen, induced a good PFC
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FIG. 1. (A) Immunogenicity of Pnu-Imune vaccine in mice. Young BALB/c mice (4 to 5 months old) were immunized i.p. with various
doses of Pnu-Imune vaccine. Five days later, pneumococcal polysaccharide (PS)-specific PFCs were assayed from the spleens and MLN
using SRBC coated with Pnu-Imune as indicator cells. (B) Kinetics of antibody response to Pnu-Imune vaccine in young BALB/c mice (4 to
5 months old) injected i.p. with the optimal dose (11.5 ,ug per mouse) of Pnu-Imune vaccine. The pneumococcal polysaccharide (PS)-specific
PFC response from spleens and MLN was measured on days 4, 5, 6, 7, and 9 postimmunization. Each datum point represents the arithmetic
mean + standard error of the PFC response observed in three to five mice. In this and other figures, datum points without error bars represent
data wherein the size of error bar was less than the size of the data point.

TABLE 1. Comparison of vaccine- and individual
polysaccharide-coated SRBC in detecting the
PFC response to Pnu-Imune

Coupling antigen
Pnu-Imune vaccine .................................
Pneumococcal type .
1.......................................................
5.......................................................
14 .....................................................
22 .....................................................
26 .....................................................
57 .....................................................
70 .....................................................

No. of (mean + SE)
spleen cells PFCs/106

1,034

+ 141

209 + 64
113 ± 7
56 + 2
45 + 4
131 + 4
94 + 16
35 + 8

a Young BALB/c mice (4 to 5 months of age) were immunized with 11.5 p.g
of Pnu-Imune vaccine. The PFC response was measured on day 5, using
SRBC coupled with vaccine or indicated polysaccharides (U.S. nomenclature
used for pneumococcal types). Sum of responses measured using SRBC
coated individually with 21 of the polysaccharides was 2,950 ± 130 PFCs/106
spleen cells.

response from these draining lymph nodes (Fig. 2B), in
agreement with our previous results (17). Four polysaccharides (types 1, 3, 5, and 19) were tested individually for the
dichotomy of response from the spleens and lymph nodes.
Consistent with the data from the whole vaccine, none of the
polysaccharides elicited a measurable response from the
peripheral lymph nodes. In the same experiment, the splenic
responses were 1,125 + 124, 923 + 143, 1,208 ± 121, and 821
± 220 PFCs/106 cells for type 1, 3, 5, and 19 polysaccharides,

respectively.
Effect of age on murine immune response to Pnu-Imune
vaccine. BALB/c mice (22 to 24 month old) were immunized
i.p. with various doses of Pnu-Imune vaccine, and the
antibody responses were measured 5 days later (Fig. 3A).
Just as in young mice, 11.5 ,ug continued to be the optimal
dose for aged mice, and the peak response was obtained on
day 5 (Fig. 3B). Similarly, the PFC response to an i.p.
challenge (181 ± 7 PFCs/106 cells) was higher than to
subcutaneous immunization (120 ± 12 PFCs/106 cells) with
the vaccine. To determine the effect of age on the immune
response to the vaccine, various age groups of BALB/c mice
were immunized i.p. with the optimal dose (11.5 ,ug/mouse)
of the Pnu-Imune vaccine. Results shown in Fig. 3C demonstrated clearly that splenic immune responses to Pnu-
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FIG. 2. (A) Unresponsiveness of peripheral lymph nodes to the
Pnu-Imune vaccine. The optimal dose (11.5 ,ug per mouse) of
Pnu-Imune vaccine was administered subcutaneously to young
BALB/c mice (4 to 5 months old) in the left armpit near the shoulder
area and into footpads. The pneumococcal polysaccharide (PS)specific PFC response in the spleens, MLN, and peripheral lymph
nodes (PLN) (brachial, axillary, cervical, popliteal, inguinal, and
periaortic) was assayed at different times after immunization. Each
datum point represents the arithmetic mean ± standard error of PFC
response observed in four to five mice. (B) The optimal dose of 50 ,ul
of 1:10 dilution of stock TNP-BA per mouse was administered
subcutaneously to young BALB/c mice. PFC response was assayed
for the spleens and peripheral lymph nodes at days 4, 5, and 7.

Imune vaccine declined steadily with increasing age of the
mice. The maximum splenic response occurred in the 4- to
5-month-old mice, and 22-month-old mice exhibited responses which were significantly less (P < 0.001) than the
maximum value. The vaccine failed to elicit antibody response from peripheral lymph nodes from mice of all age
groups. Interestingly, PFC responses in the mucosa-associated lymph nodes did not decline but instead remained
relatively constant over the entire age span studied. In this
study, mice younger than 4 months were not tested, but
other studies with individual polysaccharides demonstrated
that younger mice had reduced responses (21, 22).
To determine whether senescence had any positive effects
on the immune responses of peripheral lymph nodes to the
Pnu-Imune vaccine, we immunized 22- to 24-month-old
BALB/c mice subcutaneously with this vaccine in the left
armpit near the shoulder and into the foot pads. As shown in
Table 2, 22- to 24-month-old mice behaved like young mice
and did not show any response in the peripheral or MLN.
These lymph node cells responded well to challenge with
TNP-BA, consistent with our previous studies on lymph
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FIG. 3. (A) Dose dependency of Pnu-Imune response in aged
mice. Various doses (3.9, 11.5, 34.5, 57.6, and 115 pg per mouse) of
vaccine were injected i.p. into 22- to 24-month-old BALB/c mice.
PFC response was measured at day 5 for the spleens and MLN. (B)
Kinetics of Pnu-Imune response in aged mice. The optimal dose of
11.5 pug of vaccine was injected i.p. into 22- to 24-month-old BALB/c
mice, and the PFC response was measured on days 3, 4, 5, 7, and 9.
(C) Effect of age on the immune response to the Pnu-Imune vaccine.
Indicated age groups of BALB/c mice were immunized i.p. with the
optimal dose (11.5 pLg per mouse) of the Pnu-Imune vaccine. After 5
days, the PFC response was assayed for the spleens, MLN, and
peripheral lymph nodes. The vaccine failed to elicit any detectable
response from peripheral lymph nodes. Each datum point represents
the arithmetic mean of PFC response observed in four to five mice.
The error bars represent standard errors of the mean. PS, polysaccharide.

node responses to such antigens (15, 17). Although there was
a detectable splenic response to Pnu-Imune in these aged
mice, it was small compared with that of young mice.
The nontoxic adjuvant, MPL(A), enhances the immune
response to the vaccine. Young mice (4 to 5 months old) and
old mice (22 to 24 months old) were immunized i.p. with
various doses of MPL(A) along with an optimal dose of the
Pnu-Imune vaccine. Twenty-five micrograms of MPL(A)
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TABLE 2. PFC responses to Pnu-Imune vaccine in the spleens,
MLN, and peripheral lymph nodes of 22- to 24-month-old
BALB/c micea
No. of PFCs/106 cellsb

Antigen and site of
injection

Spleen

Peripheral

lymph

MLN

nodes'

Pnu-Imune
(Near shoulder)

(Footpads)
TNP-BA

91 ± 32
120 + 12.4
167 64

NR
NR
94 ± 2.8

NR
27 + 3
ND

swo.~~~~~~~~:
BPNU-IMUNE
PNU-IMUNE+MPL
M
SMPL

SPLEEN

was found to be optimal in enhancing the Pnu-Imune response in young and old mice, while smaller doses were
ineffective as an adjuvant and higher doses of MPL(A) (100
jig) were inhibitory in both young and old mice. At the
optimal dose, the MPL(A) adjuvant enhanced the antibody
response from the spleens of old mice (22 to 24 months) by
a factor of 10 (Fig. 4A), but there was little or no response in
mice immunized only with the adjuvant. The splenic response of young mice was also enhanced by MPL(A) but
only by a factor of about 3. The response in MLN was
enhanced by MPL(A) only in young mice. Since, in humans,
the i.p. route is not practical, we tested the ability of
MPL(A) to be used as an adjuvant if administered via the
subcutaneous route. The splenic response increased when
Pnu-Imune vaccine was administered subcutaneously along
with the MPL(A) adjuvant (Fig. 4B). The MPL(A)-induced
enhancement was greater in old mice than in young mice.
However, MPL(A) was unable to induce any Pnu-Imune
response in the draining lymph nodes of young or old mice.
Injection of MPL(A) 2 days after subcutaneous immunization with the optimal dose (11.5 ,ug) of Pnu-Imune vaccine
caused a slight increase in the numbers of IgM-secreting
pneumococcal polysaccharide-specific PFC from peripheral
draining lymph nodes (O [without MPL] versus 32 ± 5
PFCs/106 cells [with MPL]). In contrast, subcutaneous administration of MPL(A) induced a substantial enhancement
of the IgM antibody response from the spleen. This increase
was similar in magnitude to those noted in other experiments
such as those shown in Fig. 4A in which MPL(A) was
injected along with the Pnu-Imune vaccine.
The Pnu-Imune vaccine alone induced an IgM PFC response, but no IgG response, in young and old mice.
Administration of MPL(A) along with the vaccine induced
IgG3 responses in both age groups (Table 3). Yet there was
no IgGl or IgG2 response, suggesting that the response
observed with anti-IgG antibodies is mainly due to the IgG3
component. The isotype distribution of the response remained the same at later times after immunization. Notably,
the enhancing effect of MPL(A) on the Pnu-Imune response
in the spleen could be observed even at day 11 in 22-monthold mice (Fig. 5) as well as in 6- to 9-month-old mice (data
not shown). The response became undetectable by day 15.

AGED MICE

PLN

YOUNG MICE

S

N

AGED MICE

FIG. 4. (A) Effect of the adjuvant MPL(A) on the Pnu-Imune
responses of young and old mice. The optimal dose (11.5 p.g per
mouse) of Pnu-Imune vaccine along with 25 ,ug of MPL(A) per
mouse was administered i.p. to young (4- to 5-month-old) and old
(22- to 24-month-old) BALB/c mice, and 5 days later the pneumococcal polysaccharide (PS)-specific PFC response was evaluated for
spleens and MLN. Each datum point represents the arithmetic mean
± standard error of the PFC responses of three to five mice. (B)
Lack of adjuvant effect of MPL(A) on the peripheral lymph node
response to the Pnu-Imune vaccine. The optimal dose (11.5 ,ug per
mouse) of Pnu-Imune vaccine along with 25 p.g of MPL(A) per
mouse was administered to young (4- to 5-month-old) and old (22- to
24-month-old) BALB/c mice subcutaneously. Five days later, the
pneumococcal polysaccharide (PS)-specific PFC response was assayed for the spleens, MLN, and draining lymph nodes (brachial,
axillary, cervical, inguinal, popliteal, and periaortic). The arithmetic
means + standard errors of PFC responses of four to five mice are
plotted. For peripheral lymph nodes (PLN), only the response in the
presence of MPL(A) plus vaccine, which is very small, is shown.
MPL(A) alone or the vaccine alone failed to induce any response in
the lymph nodes.

DISCUSSION
An animal model system was developed to study the effect
of age on immune responses to the vaccine containing
pneumococcal polysaccharides. The commercially available
Pnu-Imune vaccine was found to be effective in inducing a
good antibody-forming cell response in the murine system.
The optimal dose requirements and the peak of the response
for the vaccine were similar to those observed with the
individual polysaccharides in mice (4). In experiments not
shown here, it was demonstrated that immunization with the
vaccine elicited measurable antibody responses against 21
polysaccharides present in the vaccine (14a).
Study of the immune responses in different lymphoid
organs demonstrated that the splenic and MLN B cells, but
not B cells from peripheral lymph nodes, responded well to
the vaccine. In this, the vaccine behaved like TNP-Ficoll
and other TI-2 antigens, as reported by us earlier (15-17).
Further, MLN responses were obtained only by i.p. challenge but not subcutaneous challenge with the vaccine (data
not shown), whereas the splenic response was induced by
either mode of immunization. These results provide an
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° The optimal dose (11.5 p.g per mouse) of Pnu-Imune vaccine or TNP-BA
(50 p1l of 1:10 dilution of the stock) was administered subcutaneously in the left
armpit near the shoulder area as well as into footpads. Antibody response was
measured 5 days later, using vaccine- or TNP-coated SRBC.
b The arithmetic mean ± standard error of the PFC responses from four
mice is shown. NR, no response; ND, not done.
c These include brachial, axillary, cervical, popliteal, inguinal, and periaortic lymph nodes.
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TABLE 3. Effect of adjuvant MPL(A) on the isotype distribution of the PFC response to Pnu-Imune vaccine'
No. of PFCs/106 spleen cellsb
Antigen

Age (mo) of mice

IgM

Pnu-Imune
Pnu-Imune + MPL(A)
Pnu-Imune
Pnu-Imune + MPL(A)
Pnu-Imune
Pnu-Imune + MPL(A)

5 to 6
5 to 6
16
16
22
22

551
838
455
867
149
638

40
2
8
20
32
+ 14

±
±
±
±
±

IgG

IgGl

IgG2

IgG3

0
140 ± 11
0
124 + 21
0
250 ± 32

0
0
0
0
0
0

0
0
0
0
0
0

0
201 ± 13
0
186 ± 14
0
180 ± 6

a The optimal dose (11.5 p.g per mouse) of Pnu-Imune vaccine along with 25 pg mouse of MPL(A) was administered i.p. to 5- to 6-, 16-, and 22-month-old
BALB/c mice. The PFC response was measured 5 days after immunization. Isotypes of the PFCs were determined as described in Materials and Methods.
Administration of MPL(A) alone failed to elicit any IgM or IgG PFC response.
' The values represent the arithmetic means ± standard errors of responses of two mice.
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DAYS POST IMMUNIZATION
FIG. 5. The adjuvant MPL(A) prolongs the immune response to
the Pnu-Imune vaccine. Old BALB/c mice (22 to 24 months old)
were immunized i.p. with 11.5 ,ug of the Pnu-Imune vaccine per
mouse along with 25 jig of MPL(A). The antibody responses were
analyzed on days 5, 7, 11, and 15 postimmunization. The response
on day 15 was too little to measure and therefore was not shown.
Each datum point represents the arithmetic mean of the PFC
response observed in four to five mice. The error bars represent the
standard errors of the mean.

proposed that the mucosa-associated lymphoid system contains a distinct lymphoid population (1, 6, 11, 23). Indeed,
the homing receptors for Peyer's patches and peripheral
lymph nodes have been found to be distinct (14). The reason
why the mucosa-associated lymphoid system remains immunologically vigorous at a time when systemic immunity
declines is not known but may be related to the constant
environmental stimulation present in the mucosal tissues.
For practical purposes, it would be valuable if an immunization protocol could recruit this system to obtain a good
antibody response to the Pnu-Imune vaccine in aged humans. Currently, we are attempting oral immunization with
the vaccine and supplementation with adjuvants to stimulate
the mucosal immune system of mice.
Studies by Tomai et al. (35) showed that MPL(A) was a
good adjuvant in restoring age-dependent losses in immune
responses to SRBC. Later Baker et al. (3) reported that
MPL(A) also enhanced the responses of young mice to type
III pneumococcal polysaccharides and suggested that
MPL(A) may be effective in overcoming the effect of suppressor cells. Even though we do not know whether the
age-associated decline in responsiveness to Pnu-Imune vaccine is a result of suppressor function, we found that
MPL(A) substantially enhanced the antibody response of
aged mice to the Pnu-Imune vaccine. Administration of
Pnu-Imune vaccine along with MPL(A) induced a response
which remained elevated up to day 11. Also, the adjuvant
induced antibodies of IgG and IgG3 subtypes, which usually
have longer half-lives than IgM (37), and thus may prolong
protective immunity. Since IgG responses are usually associated with memory, supplemental immunization with the
adjuvant might provide an opportunity to obtain secondary
responses to the Pnu-Imune vaccine. We are currently
investigating this possibility. These results are extremely
encouraging, since large doses of MPL(A) have been found
to be relatively nontoxic to humans in phase I clinical trials

(39).
Several factors may contribute to the ability of MPL(A) to
act as an adjuvant in enhancing the immune response and
inducing an isotype switch. First, MPL(A) is mitogenic to B
cells and thus may act synergistically with antigen in stimulating B cells (25). Second, MPL(A) plus trehalose dimycolate mixture activates macrophages and stimulates the production of IL-1 (10, 13, 26, 27, 41). Our studies with
TNP-Ficoll, another TI-2 antigen showed that splenic accessory cells or IL-1 could restore lymph node B-cell responses
to TI-2 antigens (17). The mechanisms by which MPL(A)
induces an IgG response to the vaccine is unknown. The IgG
responses are very much dependent on the type of T helper
cells (TH1 versus TH2) induced and the production of
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explanation for the well-known splenic dependency of murine and human immune responses to pneumococcal
polysaccharides (2, 7). Our previous studies with other TI-2
antigens indicated that a splenic accessory cell was required
to induce antibody response to TNP-Ficoll in the peripheral
lymph nodes (17). Currently, we are investigating the role of
such accessory cells in the immune responses of peripheral
lymph nodes to the Pnu-Imune vaccine.
As seen in aged humans, the immune response to the
Pnu-Imune vaccine also decreased steadily with increasing
age of the mouse. A similar age-associated decline in responsiveness of the spleen to type III polysaccharide was reported previously by Smith (31). However, the age-associated decline was limited to the splenic response. The MLN
B cells from aged mice were as effective as those from young
mice in eliciting good immune responses to the Pnu-Imune
vaccine. These findings are consistent with the hypothesis
that the mucosa-associated lymphoid system differs from the
systemic immune system with regard to its competence with
age (33). Thus, Wade and Szewczuk (40) found that antibody
responses of MLN B cells to T-dependent antigens did not
decrease with age. In addition, Thoman and Weigle (34)
reported that T-cell proliferation and interleukin 2 (IL-2)
secretion were well preserved in MLN T cells, while their
splenic counterparts exhibited age-associated defects. From
studies of lymphocyte trafficking and homing, it has been
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specific cytokines such as IL-4, gamma interferon, transforming growth factor 1B, etc. (38). Conceivably, MPL(A) is
either inducing such a T-cell helper or stimulating the
production of relevant cytokines from other accessory cells.
Currently, we are evaluating the specific subtypes of IgG and
IgA that may be induced in this response.
In summary, we have shown that murine immune responses to the Pnu-Imune vaccine declined with age as in
humans and could be enhanced with the adjuvant MPL(A).
The adjuvant was also effective in inducing an IgG response
to the vaccine. The preservation of Pnu-Imune responses in
the MLN cells of the elderly suggests that alternative strategies of immunization with the vaccine should be explored.

cyte. Nature (London) 304:30-34.
14a.Garg, M., and B. Subbarao. Unpublished data.
15. Goud, S. N., A. M. Kaplan, and B. Subbarao. 1990. Antibody
response to thymic independent-antigens in the peripheral and
mesentric lymph nodes of mice. Reg. Immunol. 3:1-7.
16. Goud, S. N., A. M. Kaplan, and B. Subbarao. 1990. Primary
antibody responses to thymus-independent antigens in the lung
and hilar lymph nodes of mice. Infect. Immun. 58:2035-2041.
17. Goud, S. N., N. Muthusamy, and B. Subbarao. 1988. Differential
responses of B cells from the spleen and lymph node to
TNP-Ficoll. J. Immunol. 140:2925-2930.
18. Gray, B. M., and H. C. Dillon. 1986. Clinical and epidemiologic
studies of pneumococcal infection in children. Pediatr. Infect.

REFERENCES
1. Allardyce, R. A., and J. Bienenstock. 1984. The mucosal immune
system in health and disease with an emphasis on parasitic
infection. Bull. W.H.O. 62:7-25.
2. Amlot, P. L., D. Grennan, and J. H. Humphrey. 1985. Splenic
dependence of the antibody response to thymus independent
(TI-2) antigens. Eur. J. Immunol. 15:508-512.
3. Baker, P. J., J. R. Hiernaux, M. B. Fauntleroy, P. W. Stashak,
B. Prescott, J. L. Cantrell, and J. A. Rudbach. 1988. Ability of
monophosphoryl lipid A to augment the antibody response of
young mice. Infect. Immun. 56:3064-3066.
4. Baker, P. J., P. W. Stashak, D. F. Amsbaugh, and B. Prescott.
1971. Characterization of the antibody response to type III
pneumococcal-polysaccharide at the cellular level. I. Dose
response studies and the effect of prior immunization on the
magnitude of the antibody response. Immunology 20:469-480.
5. Baker, P. J., P. W. Stashak, and B. Prescott. 1969. The use of
erythrocytes sensitized with purified pneumococcal polysaccharides for the assay of antibody and antibody producing cells.
Appl. Microbiol. 17:422-426.
6. Bienenstock, J. 1984. The mucosal immunological network.
Ann. Allergy 53:535-540.
7. Bohnsack, J. F., and E. J. Brown. 1986. The role of the spleen in
resistance to infection. Annu. Rev. Med. 37:49-59.
8. Bolan, G., C. V. Broome, R. R. Facklam, B. D. Plikaytis, D. W.
Fraser, and W. F. Schlech III. 1986. Pneumococcal vaccine
efficacy in selected populations in the United States. Ann.
Intern. Med. 104:1-6.
9. Callard, R. E., A. Basten, and L. K. Waters. 1977. Immune
function in aged mice. II. B-cell function. Cell. Immunol.
31:26-36.
10. Carozzi, S., M. Salit, A. Cantaluppi, M. G. Nasini, S. Barocci, S.
Cantarella, and S. Lamperi. 1989. Effect of monophosphoryl
lipid A on the in vitro function of peritoneal leukocytes from
uremic patients on continuous ambulatory peritoneal dialysis. J.
Clin. Microbiol. 27:1748-1753.
11. Cebra, J. J., P. J. Gearhart, and R. Kamat. 1977. Origin and
differentiation of lymphocytes involved in the secretory IgA
responses. Cold Spring Harbor Symp. Quant. Biol. 41:201-215.
12. Centers for Disease Control. 1984. Update: pneumococcal
polysaccharide vaccine usage. United States. Morbid. Mortal.
Weekly Rep. 33:273-281.
13. DUkstra, J., J. W. Mellors, J. L. Ryan, and F. C. Szoka. 1987.
Modulation of the biological activity of bacterial endotoxin by
incorporation into liposomes. J. Immunol. 138:2663-2670.
14. Gallatin, W. M., I. L. Weissman, and E. C. Butcher. 1983. A cell
surface molecule involved in organ specific homing of lympho-

Downloaded from http://iai.asm.org/ on February 20, 2019 by guest

ACKNOWLEDGMENTS
in part by NIH grants AI-21490 and
supported
This work was
AG-05731, funds from the Tobacco and Health Research Institute of
University of Kentucky and from the Kentucky Thoracic Society,
and Research Career Development Award K04AG00422 to Bondada
Subbarao.
Our thanks are due to Alan Kaplan, Don Cohen, and V. Udhayakumar for critical reviews of the manuscript and Charlotte Burchett
for expert secretarial assistance.

Dis. J. 5:201-207.
19. Jerne, N. K., and A. A. Nordin. 1963. Plaque formation in agar
by single antibody producing cells. Science 140:405.
20. Laforce, F. M., and T. C. Eicknoff. 1988. Pneumococcal vaccine: an emerging consensus. Ann. Int. Med. 108:757-759.
21. Mosier, D. E., and B. Subbarao. 1982. Thymus-independent
antigens: complexity of B lymphocyte activation revealed.
Immunol. Today 3:217-222.
22. Mosier, D. E., N. M. Zaldivar, and E. Goldings. 1977. Formation
of antibody in the newborn mouse: study of T-cell independent
antibody. J. Infect. Dis. 136:S14-S19.
23. Orga, P. L., and R. Dhar. 1985. Local immune responses. Br.
Med. Bull. 41:28-32.
24. Pasanen, V. J., R. Asofsky, and P. J. Baker. 1979. Synthesis of
two classes of antibody, IgM and IgG, or IgM and IgA by
identical cells. Amplification of the antibody response to pneumococcal polysaccharide type III. J. Exp. Med. 149:1227-1237.
25. Ribi, E., J. L. Cantrell, K. Takayama, N. Qureshi, J. Peterson,
and H. 0. Ribi. 1984. Lipid A and immunotherapy. Rev. Infect.
Dis. 6:567-572.
26. Ribi, E., J. L. Cantrell, K. Takayama, H. 0. Ribi, K. R. Myers,
and N. Qureshi. 1986. Modulation of humoral and cell mediated
immune responses by a structurally established nontoxic lipid
A, p. 407-420. In A. Szentivanji and H. Friedman (ed.),
Immunobiology and immunopharmacology of bacterial endotoxins. Plenum Press, New York.
27. Ribi, E., J. T. Ulrich, and K. N. Masihi. 1987.. Immunopotentiating activities of monophosphoryl lipid A, p. 101-112. In J.
Majde (ed.), Immunopharmacology of infectious diseases: vaccine adjuvants and modulators of non-specific resistance. Alan
R. Liss, Inc., New York.
28. Roghmann, K. J., P. A. Tablaski, D. W. Bentley, and G.
Schiffman. 1987. Immune response of elderly adults to pneumococcus: variation by age, sex, and functional impairment. J.
Gerontol. 42:265-270.
29. Sims, R. V., W. C. Steinmann, J. H. McConville, L. R. King,
W. C. Zwick, and J. S. Schwartz. 1988. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med.
108:653-657.
30. Siskind, G. W., P. Y. Peterson, and L. Thomas. 1963. Induction
of unresponsiveness and immunity in newborn and adult mice
with pneumococcal polysaccharide. J. Immunol. 90:929-934.
31. Smith, A. M. 1976. The effects of age on the immune response
to type III pneumococcal polysaccharide and bacterial lipopolysaccharide in BALB/c, SJL/J and C3H mice. J. Immunol.
116:469-474.
32. Subbarao, B., and D. E. Mosier. 1983. Induction of B lymphocyte proliferation by monoclonal anti-Lyb2 antibody. J. Immunol. 130:2033-2037.
33. Szewczuk, M. R., R. J. Campbell, and L. K. Jung. 1981. Lack of
age associated immune dysfunction in mucosal associated
lymph nodes. J. Immunol. 126:2200-2204.
34. Thoman, M. L., and W. 0. Weigle. 1989. The cellular and
subcellular bases of immunosenescence. Adv. Immunol. 46:
221-261.
35. Tomai, M. A., L. E. Solem, A. G. Johnson, and E. Ribi. 1987.
The adjuvant properties of a nontoxic monophosphoryl lipid A
in hyporesponsive and aging mice. J. Biol. Response Modif.
6:99-107.
36. Verghese, A., and S. L. Berk. 1983. Bacterial pneumonia in the

2336

GARG AND SUBBARAO

elderly. Medicine (Baltimore) 62:271-285.
37. Vieiza, P., and K. Rajewsky. 1988. The half lives of serum
immunoglobulins in adult mice. Eur. J. Immunol. 18:313-316.
38. Vitetta, E. S., M. T. Berton, C. Burger, M. Kepron, W. T. Lee,
and X.-M. Yin. 1991. Memory B and T cells. Annu. Rev.
Immunol. 9:143-218.
39. Vosika, G. J., C. Barr, and D. Gilbertson. 1984. Phase-1 study of
intravenous modified lipid A. Cancer Immunol. Immunother.
18:107-112.

INFECT. IMMUN.
40. Wade, A. W., and M. R. Szewczuk. 1988. Evidence for the
divergence of systemic and mucosal B-cells with age in the
primary and secondary immune responses to T-dependent antigens: route of priming influences isotype profile of antigen
specific memory and antibody secreting B-cells. Aging Immunol. Infect. Dis. 1:99-119.
41. Yarkoni, E., L. Wang, and A. Bekierkunst. 1977. Stimulation of
macrophages by cord factor and by heat-killed and living BCG.
Infect. Immun. 16:1-8.

Downloaded from http://iai.asm.org/ on February 20, 2019 by guest

